Immune Fitness Prediction

Observational Study to Determine the Association Between Self-rated, Perceived Immune Fitness (Using Questionnaire) With Biological Assessment of Immune Fitness (Immune Signatures in the Blood).

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05078346

Enrollment

Registered

2021-10-14

Start date

2021-06-02

Completion date

2022-02-03

Last updated

2022-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Brief summary

The overall objective of the study is to determine whether self-rated, perceived immune fitness (using questionnaire) is associated with biological assessment of immune fitness (immune signatures in the blood).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

35 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1. Ability to understand and sign the informed consent 2. Healthy adult men and/or women, 35-65 years old 3. BMI \>18 and \<30 kg/m2

Exclusion criteria

1. Volunteer who cannot be expected to comply with the protocol 2. Individuals with self-reported chronic disease; or who have any clinical condition which the investigator deems relevant for exclusion from the study, 3. Individuals with an impaired immune system that may confound immune response testing; i.e. any condition that impairs participant immune response through either the condition itself or through the treatment of the condition, 4. Family or hierarchical relationships with Clinical Innovation Lab at Nestlé Research, Lausanne, Switzerland

Design outcomes

Primary

Measure	Time frame	Description
Relative quantification of immune protein in plasma	6 - 12 months after the start of the trial	Proteomic analysis in plasma by proximity extension assay
Percentage of different immune cell types in whole blood	6 - 12 months after the start of the trial	Immune cell type profiling in whole blood by mass cytometry
Amount of cytokines expressed by peripheral blood mononuclear cells	6 - 12 months after the start of the trial	Cytokine quantification by proximity extension assay
Amount of analytes in serum	6 - 12 months after the start of the trial	Blood chemistry

Countries

Switzerland

Outcome results